Watanabe Taiji, Kubota Sunao, Nagaya Masaki, Ozaki Shoichi, Nagafuchi Hiroko, Akashi Katsuya, Taira Yasuhiko, Tsukikawa Satoshi, Oowada Shigeru, Nakano Suehiro
Department of General Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
J Surg Res. 2005 Mar;124(1):59-66. doi: 10.1016/j.jss.2004.10.019.
High-mobility group 1 (HMGB-1) is a late mediator of endotoxin lethality in mice. The release of HMGB-1 is delayed compared to other proinflammatory cytokines that mediate shock and tissue injury. The purpose of this study was to investigate the role of HMGB-1 levels in response to hepatic ischemia, hepatic I/R injury, and the relationship between changes in HMGB-1 and other cytokines.
Three murine models were employed: our robust model of segmental hepatic warm ischemia (SHWI), a model of partial hepatic ischemia/reperfusion injury (PHIRI), and a model of total hepatic ischemia/reperfusion injury (THIRI). Over a 48-h period following ischemic insult and reperfusion using these models, serum HMGB-1 concentrations, concentrations of HMGB-1 in ischemic and nonischemic lobes, and serum concentrations of TNF-alpha and IL-6 levels were determined in mice. An anti-HMGB-1 antibody treatment was used in SHWI and THIRI to evaluate what aspects of response to ischemia and reperfusion were potentially mediated by HMGB-1.
Hepatic HMGB-1 tissue concentrations exhibited biphasic changes in SHWI mice, which were increased in the ischemic lobes relative to nonischemic lobes at 12 h but decreased relative to nonischemic lobes at 24 h after ischemic insult. These results suggested that HMGB-1 was released into the systemic circulation by necrotic cells over the first 12 h but this process may be complete by 24 h postischemia. By 6 to 12 h after SHWI, serum TNF-alpha began to increase significantly and continued to increase for 18 h, followed by a sudden decline. Similarly, serum IL-6 increased over 1-3 h after SHWI and then decreased over the next 6 h. Treatment with an anti-HMGB-1 antibody significantly prolonged survival time in SHWI and THIRI.
HMGB-1 plays a significant role in the response to hepatic ischemia and hepatic ischemia/reperfusion injury. The present study demonstrated a time-dependent production of HMGB-1 following hepatic warm ischemia in mice. The inherent HMGB-1 in ischemic areas was exhausted and HMGB-1 may be released by necrotic cells. HMGB-1 activation is involved in immediate proinflammatory stress response to I/R and anti-HMGB-1 antibody treatment remarkably improved survival. We demonstrated that systemic HMGB-1 accumulation was measured at an earlier phase of the hepatic ischemia and ischemia/reperfusion injury model than LPS-induced endotoxemia.
高迁移率族蛋白1(HMGB - 1)是小鼠内毒素致死的晚期介质。与介导休克和组织损伤的其他促炎细胞因子相比,HMGB - 1的释放延迟。本研究的目的是探讨HMGB - 1水平在肝脏缺血、肝脏缺血/再灌注损伤反应中的作用,以及HMGB - 1变化与其他细胞因子之间的关系。
采用三种小鼠模型:我们建立的节段性肝脏热缺血(SHWI)的可靠模型、部分肝脏缺血/再灌注损伤(PHIRI)模型和全肝脏缺血/再灌注损伤(THIRI)模型。使用这些模型在缺血损伤和再灌注后的48小时内,测定小鼠血清HMGB - 1浓度、缺血和非缺血肝叶中HMGB - 1的浓度以及血清肿瘤坏死因子 - α(TNF - α)和白细胞介素 - 6(IL - 6)水平。在SHWI和THIRI模型中使用抗HMGB - 1抗体治疗,以评估HMGB - 1可能介导的缺血和再灌注反应的哪些方面。
SHWI小鼠肝脏HMGB - 1组织浓度呈现双相变化,缺血损伤后12小时,缺血肝叶中HMGB - 1相对于非缺血肝叶增加,但在24小时时相对于非缺血肝叶减少。这些结果表明,HMGB - 1在最初12小时内由坏死细胞释放到体循环中,但这个过程在缺血后24小时可能完成。SHWI后6至12小时,血清TNF - α开始显著增加,并持续增加18小时,随后突然下降。同样,血清IL - 6在SHWI后1 - 3小时增加,然后在接下来的6小时内下降。用抗HMGB - 1抗体治疗可显著延长SHWI和THIRI小鼠的存活时间。
HMGB - 1在肝脏缺血和肝脏缺血/再灌注损伤反应中起重要作用。本研究证明了小鼠肝脏热缺血后HMGB - 1的产生具有时间依赖性。缺血区域内固有的HMGB - 1被耗尽,HMGB - 1可能由坏死细胞释放。HMGB - 1的激活参与了对缺血/再灌注的即时促炎应激反应,抗HMGB - 1抗体治疗显著提高了存活率。我们证明,在肝脏缺血和缺血/再灌注损伤模型中,全身HMGB - 1的积累比脂多糖诱导的内毒素血症更早被检测到。